Two more TIGIT setbacks

After a rollercoaster 2023 for TIGIT inhibition, the field just received two more blows. Today, Coherus ended its collaboration with Junshi Biosciences, while at the JP Morgan healthcare conference yesterday Roche slipped out news of yet another delay to a key trial of its contender tiragolumab. The final overall survival analysis of Roche’s Skyscraper-01 NSCLC trial is now due in the second half of 2024, presumably because events are accruing more slowly than expected. Hopes of a positive result were boosted last year by leaked interim data. Things look less rosy for CHS-006, the project Coherus and Junshi had been developing together; the former said in an SEC filing that it exited the deal after its acquisition of Surface Oncology in June and a resulting pipeline prioritisation. The move echoes Novartis’s decision to walk away from BeiGene’s ociperlimab last July. One group keeping the TIGIT faith is iTeos, whose GSK-partnered asset belrestotug is set to yield data this year from the Galaxies Lung-201 trial in first-line NSCLC, where it is being given alongside Jemperli. However, long-promised details of a planned phase 3 study have not yet emerged, and GSK did not mention TIGIT during its JP Morgan presentation on Tuesday.